Increased Serum Soluble Interleukin-2 Receptor Associated with Severity of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increased Serum Soluble Interleukin-2 Receptor Associated with Severity of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Authors
Keywords
-
Journal
International Journal of Chronic Obstructive Pulmonary Disease
Volume Volume 16, Issue -, Pages 2561-2573
Publisher
Informa UK Limited
Online
2021-09-07
DOI
10.2147/copd.s321904
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study
- (2020) Eirini Mavropoulou et al. PLoS One
- Value of serum soluble interleukin-2 receptor as a diagnostic and predictive biomarker in sarcoidosis
- (2020) MC Schimmelpennink et al. Expert Review of Respiratory Medicine
- Severity of COPD and its relationship with IL-10
- (2018) Bruna S.A. Silva et al. CYTOKINE
- Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease
- (2018) Tomohiro Handa et al. Modern Rheumatology
- Phenotyping COPD exacerbations using imaging and blood-based biomarkers
- (2018) Nawaf M Alotaibi et al. International Journal of Chronic Obstructive Pulmonary Disease
- Immunodeficiency in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- (2018) Sheling Xie et al. INFLAMMATION
- Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Spencer L James et al. LANCET
- Biomarkers of collagen turnover are related to annual change in FEV1 in patients with chronic obstructive pulmonary disease within the ECLIPSE study
- (2017) Diana J. Leeming et al. BMC Pulmonary Medicine
- The Expression of IL-6, TNF-α, and MCP-1 in Respiratory Viral Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
- (2017) Jingtong Zheng et al. Journal of Immunology Research
- Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort
- (2017) MeiLan K Han et al. Lancet Respiratory Medicine
- Inflammatory mechanisms in patients with chronic obstructive pulmonary disease
- (2016) Peter J. Barnes JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Biomarker Development for Chronic Obstructive Pulmonary Disease. From Discovery to Clinical Implementation
- (2015) Don D. Sin et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Airway IL-1β and Systemic Inflammation as Predictors of Future Exacerbation Risk in Asthma and COPD
- (2015) Juan-juan Fu et al. CHEST
- IL2RA is associated with persistence of rheumatoid arthritis
- (2015) H.W. van Steenbergen et al. ARTHRITIS RESEARCH & THERAPY
- Cellular and Molecular Mechanisms of Chronic Obstructive Pulmonary Disease
- (2013) Peter J. Barnes CLINICS IN CHEST MEDICINE
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
- (2010) Thomas R. Malek et al. IMMUNITY
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
- (2010) John R. Hurst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarkers in COPD
- (2010) Mario Cazzola et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Serum soluble interleukin 2 receptor α in human cancer of adults and children: a review
- (2008) E. Bien et al. BIOMARKERS
- IL-2 signaling and CD4+CD25+Foxp3+ regulatory T cells
- (2007) Laurence et al. Frontiers in Bioscience-Landmark
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started